As Congress works to reauthorize for the seventh time pharmaceutical user fee legislation, it is overlooking what should be part of virtually every law that affects industry these days: the climate crisis.
The Prescription Drug User Fee Act, initially established in 1992, primarily authorizes the Food and Drug Administration to collect user fees from industry that fund review and approval of patented and generic drugs, biosimilars, and medical devices, as well as related FDA performance goals. This update would reauthorize the act for fiscal year 2023 through 2027.
Click this link for the original source of this article.
Author: David Introcaso
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
